PolyPEPI SCoV 2 vaccine
Alternative Names: Coronavirus vaccine - PepTC Vaccines Limited; PolyPEPI-SCoV-2 vaccine - PepTC Vaccines LimitedLatest Information Update: 28 Jul 2024
At a glance
- Originator Treos Bio
- Developer PepTC Vaccines Limited
- Class COVID-19 vaccines; Peptide vaccines
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in United Kingdom (Parenteral)
- 26 Oct 2020 Pharmacodynamics data from a preclinical study in COVID-2019 infections released by PepTC Vaccines
- 22 Oct 2020 PepTC Vaccines received pre-IND regulatory confirmations from the US FDA, MHRA and PEI